TC BioPharm Plans Preclinical Studies for Monkeypox Treatment

EDINBURGH, Scotland, Sept. 6, 2024 -- TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company listed on NASDAQ under the ticker TCBP, announced its plans to initiate preclinical studies for its leading therapeutic, TCB 008, aimed at treating monkeypox.

TCB 008 is an allogeneic unmodified cell therapy comprised of activated and expanded gamma delta T (GDT) cells. The company anticipates its application in addressing the global health crisis posed by monkeypox. Given the highly contagious nature of monkeypox, TC BioPharm plans to collaborate with a prominent Infectious Disease Center or a university with similar affiliations to expedite the Proof-of-Concept and preclinical studies.

CEO Bryan Kobel commented on the promising potential of gamma delta T-cells in generating a robust immune response to viral infections, as supported by several academic papers. Kobel emphasized the company's commitment to broadening the therapeutic applications of TCB 008, particularly in responding swiftly to aggressive viral infections. The ability to deploy a frozen/thawed product to patients could not only reduce mortality and prolonged viral infections but might also help in curbing the spread of the disease, preventing a global pandemic. This potential presents a substantial global market opportunity. Kobel expressed eagerness in keeping investors informed about the program's progress.

Monkeypox, scientifically referred to as mpox, is caused by a virus belonging to the genus Orthopoxvirus, which has two distinct clades: clade I and clade II. Symptoms typically include a skin rash or mucosal lesions lasting 2-4 weeks, along with fever, headaches, muscle aches, back pain, low energy, and swollen lymph nodes. Transmission occurs through physical contact with infected individuals, contaminated materials, or infected animals. The 2022-2023 global outbreak was attributed to a strain known as clade IIb.

About TC BioPharm (Holdings) PLC:
TC BioPharm is dedicated to the discovery, development, and commercialization of gamma-delta T cell therapies for cancer treatment. They have demonstrated human efficacy data in treating acute myeloid leukemia. Gamma-delta T cells are unique immune cells that merge properties of both the innate and adaptive immune systems, allowing them to distinguish between healthy and diseased tissues naturally.

As a leader in the field, TC BioPharm is the first to conduct phase II/pivotal clinical studies in oncology using gamma-delta T cell therapies. The company is currently managing two investigator-initiated clinical trials for its unmodified gamma-delta T cell products. These include a Phase 2b/3 pivotal trial for treating acute myeloid leukemia, utilizing its proprietary allogeneic CryoTC technology to distribute frozen products to clinics globally.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!